Sugi Predict

Sugi Predict / Targets / SKP2

SKP2

S-phase kinase-associated protein 2 · Q13309 · SKP2 on Sugi Atlas →

33,374 patent compounds predicted against SKP2, 15,844 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Selexipag Selexipag (SCHEMBL674122) 1.00 8/20
SCHEMBL618489 SCHEMBL618489 0.50 8/20
Laselipag Laselipag (SCHEMBL676234) 0.77 6/20
SCHEMBL383762 SCHEMBL383762 0.53 5/20
SCHEMBL973782 SCHEMBL973782 0.45 5/20
SCHEMBL616986 SCHEMBL616986 0.49 4/20
SCHEMBL617002 SCHEMBL617002 0.49 4/20
SCHEMBL28868 SCHEMBL28868 0.45 4/20
SCHEMBL173464 SCHEMBL173464 0.44 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL345453) 0.44 4/20
SCHEMBL918377 SCHEMBL918377 0.44 4/20
SCHEMBL615185 SCHEMBL615185 0.42 4/20
SCHEMBL617577 SCHEMBL617577 0.66 3/20
SCHEMBL530038 SCHEMBL530038 0.61 3/20
SCHEMBL617173 SCHEMBL617173 0.54 3/20
SCHEMBL617174 SCHEMBL617174 0.54 3/20
SCHEMBL526709 SCHEMBL526709 0.53 3/20
SCHEMBL614945 SCHEMBL614945 0.51 3/20
SCHEMBL476267 SCHEMBL476267 0.46 3/20
SCHEMBL486015 SCHEMBL486015 0.44 3/20

Clinical trials — most relevant to SKP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas PHASE1/PHASE2COMPLETED
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC PHASE2NOT_YET_RECRUITING
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery PHASE1COMPLETED
ABEMA Alone or in COMBO With MK-6482 PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SKP2 binder may also engage these)

ProteinNameSimilarity
Q9Z0Z3 — 0.995 Q9Z0Z3 →
Q8C2S5 — 0.984 Q8C2S5 →
Q80ZD7 — 0.979 Q80ZD7 →
Q4KLV2 — 0.979 Q4KLV2 →
Q96NW4 — 0.979 Q96NW4 →
P0DM44 — 0.979 P0DM44 →
Q7T0L6 — 0.978 Q7T0L6 →
Q2HJ90 — 0.978 Q2HJ90 →
Q5REW9 — 0.978 Q5REW9 →
Q3URY6 — 0.978 Q3URY6 →
Q5R6E1 — 0.977 Q5R6E1 →
E5DHB5 — 0.977 E5DHB5 →
Q5F479 — 0.977 Q5F479 →
Q9Y546 — 0.977 Q9Y546 →
Q80ZD8 — 0.977 Q80ZD8 →
Q9EPX5 — 0.977 Q9EPX5 →
Q0VD31 — 0.977 Q0VD31 →
Q2QLA4 — 0.977 Q2QLA4 →
Q8C0W1 — 0.976 Q8C0W1 →
B0BLW3 — 0.976 B0BLW3 →
Q09YN0 — 0.976 Q09YN0 →
Q8BH70 — 0.975 Q8BH70 →
Q0V9Y8 — 0.975 Q0V9Y8 →
Q9ZWC6 — 0.975 Q9ZWC6 →
Q8R2U7 — 0.975 Q8R2U7 →
Q8VD46 — 0.975 Q8VD46 →
A0JM56 — 0.975 A0JM56 →
FASTKD5 FAST kinase domain-containing protein 5, mitochondrial 0.975 landscape →
O70173 — 0.975 O70173 →
A2VE78 — 0.975 A2VE78 →